Related Experiment Videos
Targeted cytokine delivery to neuroblastoma
P K Dehal1, M J Embleton, J T Kemshead
1Medical Oncology, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester M20 4BX, UK.
Biochemical Society Transactions
|August 28, 2002
Summary
Researchers created a fusion protein combining granulocyte/macrophage colony-stimulating factor (GM-CSF) with a targeting antibody fragment. This novel protein activates immune cells against neuroblastoma, showing potential for targeted cancer therapy.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Neuroblastoma, a pediatric cancer, often expresses Neural Cell Adhesion Molecule (NCAM).
- Targeting NCAM on neuroblastoma cells presents a potential therapeutic strategy.
- Cytokines like GM-CSF are crucial for immune cell proliferation and function.
Purpose of the Study:
- To construct a fusion protein linking GM-CSF to an anti-NCAM single-chain Fv fragment (scFv D29).
- To evaluate the expression and binding characteristics of the scFv D29-GM-CSF fusion protein.
- To assess the fusion protein's ability to activate immune cells against NCAM-expressing neuroblastoma cells.
Main Methods:
- Construction and mammalian cell expression of the scFv D29-GM-CSF fusion protein using retroviral and adenoviral vectors.
- Enzyme-Linked Immunosorbent Assay (ELISA) to confirm binding to recombinant NCAM.
- Flow Cytometry (FACS) analysis to assess binding to neuroblastoma cell lines (SKNBE and N2A-rKNIE).
- FDC-P1 cell proliferation assays to evaluate GM-CSF activity.
- In vitro clonogenic assays to assess immune cell-mediated neuroblastoma growth inhibition.
Main Results:
- The scFv D29-GM-CSF fusion protein was successfully expressed and demonstrated binding to immobilized NCAM.
- Binding was confirmed on human (SKNBE) and engineered murine (N2A-rKNIE) neuroblastoma cell lines.
- The fusion protein stimulated the proliferation of GM-CSF-dependent FDC-P1 cells.
- In vitro assays showed selective growth inhibition of neuroblastoma cells by murine lymphoid cells upon treatment with the fusion protein.
Conclusions:
- The scFv D29-GM-CSF fusion protein is a functional construct capable of targeting NCAM-expressing neuroblastoma cells.
- The fusion protein retains GM-CSF activity, stimulating immune cell proliferation.
- This novel fusion protein demonstrates potential for activating immune responses against neuroblastoma, warranting further investigation for therapeutic applications.